alexa Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmacoeconomics: Open Access

Author(s): Brown R, Turk F, Dale P, Bousquet J

Abstract Share this page

Abstract BACKGROUND: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real-life studies that assess the effectiveness of treatment are of particular interest. METHODS: We determined the incremental cost-effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from the real-life 1-year randomized open-label study (ETOPA) and using Canada as a reference country. Only patients receiving high-dose ICS plus LABA were included in the analysis, reflecting the EU label for omalizumab. Costs and quality-adjusted life years (QALYs) gained were used to calculate the ICER for omalizumab (cost/QALY). Probabilistic sensitivity analysis was performed to determine the 95\% confidence interval and one-sided sensitivity analyses were performed. RESULTS: The base case lifetime analysis of standard therapy vs standard therapy plus add-on omalizumab for the first 5 years, gave an ICER of 31,209 Euro. Probabilistic sensitivity analysis indicated that the 95\% confidence interval around the ICER was 27,739-40,840 Euro. The ICER range for one-way sensitivity analyses was 23,762 Euro without discounting to 66,443 Euro without inclusion of asthma-related mortality. CONCLUSIONS: This study demonstrates that add-on omalizumab therapy is cost-effective in patients with severe persistent allergic asthma. This article was published in Allergy and referenced in Pharmacoeconomics: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • Clinical Trials
    September 11-13, 2017 San Antonio, Texas, USA

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords